IntroductIon
Obesity and its related metabolic disorders are major health issues affecting all age groups (Spiegelman and Flier, 2001; Zimmet et al., 2001; Després and Lemieux, 2006) . Unlike most other tissues in the body, adipose tissue, especially white adipose tissue (WAT), relentlessly undergoes expansion and shrinkage in response to metabolic demands. Under physiological conditions, brown adipose tissue (BAT) possesses an exceptionally high number of microvessels, rendering this tissue one of the most highly vascularized tissues in the body (Cao, 2007 (Cao, , 2010 Yang et al., 2013) . The adipose vascular density can be further increased upon metabolic activation, such as cold-or drug-induced browning and nonshivering thermogenesis (Xue et al., 2009; Dong et al., 2013; Seki et al., 2016) . Blood vessels are thought to play an adoptive role in coping with metabolic changes of adipocytes (Asano et al., 1997; Tonello et al., 1999) . However, this view has recently been changed by the fact that adipose vasculature also play a prominent role in controlling adipocyte functions Seki et al., 2016) . For example, under cold exposure, endothelial cells (ECs) in angiogenic vessels produce paracrine factors to control browning of subcutaneous WAT (subWAT) and visceral WAT (visWAT; Seki et al., 2016) . In addition to paracrine regulation, cells of the vessel wall, including endothelial and perivascular cells, also serve as a reservoir of stem cells for differentiation into preadipocytes and, subsequently, adipocytes (Tang et al., 2008; Tran et al., 2012) .
To switch on an angiogenic phenotype, adipocytes, and likely other cell types in the adipose microenvironment, produce high levels of angiogenic factors. Vascular endothelial growth factor (VEGF) is expressed in adipose tissues and its expression is elevated under a browning condition (Sung et al., 2013; During et al., 2015) . It has been reported that VEGF induces a browning phenotype in the adipose tissue (Xue et al., 2009; Sun et al., 2012; Sung et al., 2013; Seki et al., 2016) . VEGF binds to its tyrosine kinase receptors, VEG FR1 and VEG FR2, to display various biological functions (Ferrara et al., 2003; Cao, 2009; Shibuya, 2014) . Although expression of VEG FR2 is relatively restricted to vascular ECs, VEG FR1 is widely expressed in non-ECs (Shibuya, 2006) . It is generally believed that VEG FR2 is the functional receptor that transduces signals for angiogenesis, vascular permeability, vascular survival, and remodeling (Cao, 2009) . In contrast to VEG FR2, biological functions of VEG FR1 remain largely undefined although numerous studies claim controversial findings (Lyden et al., 2001; Autiero et al., 2003; Boulton et al., 2008; Li et al., 2015; Otowa et al., 2016) . Within the VEGF family, VEGF (also called VEGF-A), placental growth factor (PlGF), and VEGF-B are all able to bind to VEG FR1 (Cao, 2009) . Very recently, VEGF-B was reported to induce angiogenesis through the VEG FR1 signaling pathway in adipose tissue (Robciuc et al., 2016) . However, the molecular mechanisms that underlie the VEG FR1-mediated signaling are still unclear. It is Angiogenesis plays an instrumental role in the modulation of adipose tissue mass and metabolism. targeting adipose vasculature provides an outstanding opportunity for treatment of obesity and metabolic disorders. Here, we report the physiological functions of VEG Fr1 in the modulation of adipose angiogenesis, obesity, and global metabolism. Pharmacological inhibition and genetic deletion of endothelial VEG Fr1 augmented adipose angiogenesis and browning of subcutaneous white adipose tissue, leading to elevated thermogenesis. In a diet-induced obesity model, endothelial-VEG Fr1 deficiency demonstrated a potent anti-obesity effect by improving global metabolism. Along with metabolic changes, fatty liver and insulin sensitivity were also markedly improved in VEG Fr1-deficient high fat diet (HFd)-fed mice. together, our data indicate that targeting of VEG Fr1 provides an exciting new opportunity for treatment of obesity and metabolic diseases, such as liver steatosis and type 2 diabetes. In this study, we took powerful genetic approaches to specifically delete VEG FR1 from vascular ECs without impairing this receptor signaling in other cell types. Furthermore, we employed physiologically relevant animal models without introducing any additional factors or other invasive procedures. Blocking VEG FR1 alone, but not VEG FR2, produced a remarkable browning phenotype of subWAT and visWAT. It was surprising that deletion of EC VEG FR1 resulted in a marked increase of vascular density in WATs, indicating the negative role of this receptor on angiogenesis. Targeting VEG FR1 alone produced overt anti-obesity and anti-diabetic effects in obese mice. Thus, our findings provide novel mechanistic insights into the vascular role of the modulation of adipocyte metabolism and pave a new avenue for the development of drugs targeting obesity and metabolic diseases.
Ablation of endothelial VEG FR1 improves metabolic dysfunction by inducing adipose tissue browning
VEGF was the primary driving force for enhanced angiogenesis. Together, these findings suggest that VEGF mediates the anti-VEG FR1-induced angiogenesis in WAT.
To gain further mechanistic insights of the signaling pathway of anti-VEG FR1-triggered angiogenesis, a pharmacological approach of simultaneous inhibition of VEG FR1 and VEG FR2 was used in our study. Noticeably, the combination of anti-VEG FR1 and anti-VEG FR2 completely abolished the anti-VEG FR1-induced angiogenesis and WAT browning (Fig. 1 E) . These data indicate that VEG FR2 is the crucial receptor for transducing the angiogenic signal. In support of this view, anti-VEG FR1 treatment was able to induce VEG FR2 phosphorylation (Fig. 1 F) . Together with the data on the combination of anti-VEG FR1 with anti-VEGF treatment, it is clear that the VEGF-VEG FR2 signaling is responsible for the angiogenic phenotype.
Anti-VEG Fr1 induces WAt browning
We next studied the impact of VEG FR1 blockade on adipocytes in various adipose depots. Histological analysis showed that VEG FR1 inhibition markedly decreased the mean size of adipocytes, exhibiting dense and irregular adipocyte cell shapes ( Fig. 1 G and Fig. S1, A and B) . High-density, irregular cellular networks existed in the VEG FR1 blockade-treated subWAT, visWAT, and BAT ( Fig. 1 G and Fig. S1 , A-D). Consistently, mRNA and protein expression levels of uncoupling protein 1 (UCP1) were significantly increased in the anti-VEG FR1-treated subWAT (Fig. 1, G and H) . Additionally, Cox8b, as a browning marker, was elevated upon anti-VEG FR1 treatment (Fig. 1 H) . By contrast, UCP1 expression levels were not altered by blocking VEG FR2 ( Fig. 1 G and Fig. S1 , A and B). UCP1 expression was also markedly increased in anti-VEG FR1-treated visWAT (Fig. S1, A and B) . Systemic anti-VEG FR1 treatment also increased UCP1 expression in BAT (Fig. S1 , C and D). Smaller adipocytes and higher UCP1 expression in VEG FR1-treated WATs and BAT might suggest the activation of nonshivering thermogenesis by the VEG FR1 blockade. In contrast, anti-VEG FR1 treatment did not alter the vascularity of liver and skeletal muscle tissue, as previously described .
Knowing that a VEG FR1 blockade induced a browning phenotype, we measured metabolism of nonshivering thermogenesis. Notably, anti-VEG FR1 markedly enhanced the norepinephrine (NE)-induced, nonshivering thermogenesis (Fig. 1 I) . By contrast, systemic treatment with an anti-VEG FR2 neutralizing antibody did not significantly affect thermogenesis-related metabolism. These data show that blocking VEG FR1 alone is able to augment a browning phenotype in WAT. Thus, VEG FR1 plays a crucial role in regulating the physiological functions of adipose tissues.
time-course analysis of sequential events of angiogenesis and WAt browning
To address the sequence of adipose angiogenesis and adipocyte browning, we performed a time-course experiment to tightly monitor vessel growth and the WAT browning phenotype. As shown in Fig. S1 , a significant increase of vascularity already occurred at day 2 after anti-VEG FR1 treatment. The vessel density continued to increase during the 10-d experimental setting (Fig. S1, F and G) . Intriguingly, adipocyte sizes were not altered until day 4 (Fig. S1, F and G) . Similarly, UCP1 expression levels in anti-VEG FR1-treated subWAT were barely detectable during the first 4-d period relative to those of controls (Fig. S1, F and G) . At day 4, there was nearly a threefold increase of vessel density without changing adipocyte size or UCP1 expression. These data indicate that angiogenesis occurred before WAT browning in our experimental setting. + vessels (red) and PERI + adipocytes (blue; n = 5 mice/group; n = 10 random fields/group for quantifications). (d) Quantitative analysis of Vegfa, Vegfb, and Plgf mRNA expression levels by qPCR (n = 6-8 samples/group). (E) Immunohistological staining of CD31 + (red) microvessels and PERI + adipocytes of NIIgG, VEGF blockade, and anti-VEG FR2 in the presence and absence of anti-VEG FR1 treatment (n = 8 mice/group). Data were quantified (n = 10 random fields). (F) Western immunoblotting analysis of VEG FR2 phosphorylation of NIIgG-and anti-R1-treated subWAT in WT C57Bl/6 mice (n = 4 samples/group). β-Actin indicates loading levels. (G) H&E staining of adipose tissues. Double-arrowed bars indicate adipocyte diameters. PERI + (green) and UCP1 + adipocytes (red) of NIIgG, anti-VEG FR1, and anti-VEG FR2 in the presence and absence of anti-VEG FR1-treated subWAT of C57Bl/6 mice (n = 5 mice/group). Arrows point to UCP1-positive signals. Data were quantified (n = 10 random fields/group). (H) qPCR quantification of Ucp1, Cox8b, Pparga1, and Prdm16 mRNA expression levels in various agent-treated subWAT samples (n = 10 samples/group). (I) NE-stimulated, nonshivering thermogenesis in NIIgG-, anti-VEG FR1-, and anti-VEG FR2-treated C57Bl/6 mice (n = 5 mice/group). *, P < 0.05; **, P < 0.01; n.s. = not significant by the standard Student's t test for pair comparisons and ANO VA analysis for multiple factors. Data are presented as means ± SEM. Bars, 50 µm. Experiments were independently repeated three times.
Reduction of adipocyte size and increase of UCP1 expression only occurred at day 7 (Fig. S1, F (Fig. 2 A) . Similar to anti-VEG FR1 treatment, the subWAT of Flt1 f/f ;Rosa26-Cre-ER T2 mice also contained an increased number of microvessels, which showed a significant increase of Ki67 + proliferating ECs (Fig. 2, A and B) . Quantification of CD31 protein levels further supported the increase of vascularity in subWAT in Flt1 f/f ;Rosa26-Cre-ER T2 mice versus that of control mice (Fig. 2 C) . Consequently, UCP1 expression levels were also markedly elevated in the subWAT of Flt1 f/f ;Rosa26-Cre-ER T2 mice relative to those of WT mice (Fig. 2, A and B) . Deletion of VEG FR1 augmented a robust angiogenic response in visWAT and BAT, exhibiting a greater density of CD31 + microvessels (Fig. S2 , A-D). Furthermore, UCP1 expression levels in the visWAT of Flt1 f/f ; Rosa26-Cre-ER T2 mice were significantly higher than those of WT control mice (Fig. S2, A and B) . Thus, systemic VEG FR1 deletion produced a functional impact on both WATs and BATs. Again, during this short experimentation period, the total mass of browning WAT and BAT was not significantly altered in Flt1 f/f ;Rosa26-Cre-ER T2 mice relative to control mice (Fig. S2 E) . The nonshivering thermogenesis was significantly increased in Flt1 f/f ;Rosa26-Cre-ER T2 mice (Fig. 2 D) . Taken together, genetic ablation of VEG FR1 validates the physiological function of this receptor in modulation of adipose metabolism.
Endothelial deletion of VEG Fr1 induces WAt browning
Because blood vessel ECs are not the only VEG FR1-expressing cell type (Shibuya, 2006 (Shibuya, , 2014 , we investigated the impact of EC VEG FR1 deletion on adipose angiogenesis and WAT browning. We generated two endothelial cell-specific VEG FR1-deletion mouse strains, Flt1 mice also contained an increased number of microvessels and exhibited a browning phenotype without affecting the total adipose mass (Fig. S3 , B-D). Because Tie2 expression is not restricted to vascular ECs (Welford et al., 2011) , we created another genetic strain of mice carrying a specific deletion of VEG FR1 in ECs using the cadherin promoter-inducible Cre system. ;Cdh5-Cre-ER T2 mice. These results indicate the physiological functions of VEG FR1 in modulating physiological metabolisms. We further investigated the possibility of a combination treatment with the deletion of VEG FR1 and WAT browning agents, such as catecholamine and cold, to produce a combination treatment with greater effects on browning. We employed a β3 adrenoceptor agonist, CL316,243 (CL), treatment to Flt1 f/f ;Cdh5-Cre-ER T2 mice. Deletion of VEG FR1 further augmented CL-induced angiogenesis and browning in subWAT compared with CL-treated WT control mice (Fig. 4 , F and G). It was plausible that macrophages, especially the alternatively activated macrophages (M2) macrophage population might contribute to WAT browning, as shown in other experimental settings (Nguyen et al., 2011; Shan et al., 2017) . To investigate this possibility, we measured the total number of macrophages and M2 macrophage polarization. As shown Fig. S4 , the total number of macrophages by immunohistological staining with macrophage-specific marker and the M2 macrophage subpopulation by qPCR analysis remained unchanged. These findings demonstrate that VEG FR1 in vascular ECs, but not in other cells, plays crucial roles in the modulation of adipose tissue metabolism. ;Rosa26-Cre-ER T2 mice (n = 5 mice/group). Mice were sacrificed 10 d after tamoxifen treatment. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by the standard Student's t test for pair comparisons. Bars, 50 µm. Data are presented as means ± SEM. Experiments were independently repeated three times. deletion of endothelial VEG Fr1 ameliorates obesity and metabolic dysfunctions Next, we employed high fat diet (HFD) to induce obesity in Flt1 f/f ;Cdh5-Cre-ER T2 mice. It was interesting that Flt1 f/f ; Cdh5-Cre-ER T2 mice showed an overt lean phenotype compared with WT control mice (Fig. 5 A) . HFD-induced body weight and BMI gains were markedly reduced relative to controls (Fig. 5, B and C) . However, food intake remained the same in Flt1 f/f ;Cdh5-Cre-ER T2 and WT mice (Fig. 5 C) , indicating no impact on food intake after removal of endothelial VEG FR1. Analysis of body composition demonstrated a significant reduction of subWAT, visWAT, and even BAT masses (Fig. 5 D) . Flt1 f/f ;Cdh5-Cre-ER T2 mice demonstrated marked improvement in lipid profile by decreasing blood levels of free fatty acid (FFA), glycerol, cholesterol, triglyceride (TG), glucose, and insulin (Fig. 5 E) . These results show that elimination of endothelial VEG FR1 significantly ameliorated dysfunctions of lipid and glucose metabolism. ;Tie2-Cre-ER T2 subWAT (n = 6 samples/group). Mice were sacrificed 8 d after tamoxifen treatment. *, P < 0.05; **, P < 0.01 by the standard Student's t test for pair comparisons. Bars, 50 µm. Data are presented as means ± SEM. Experiments were independently repeated twice.
In support of this notion, Flt1 f/f ;Cdh5-Cre-ER T2 mice showed considerable improvement in glucose clearance and insulin tolerance relative to HFD-fed control animals (Fig. 5, F and G), indicating that targeting of this receptor provides an opportunity for treatment of type 2 diabetes. Notably, EC deletion of VEG FR1 showed obvious decreases of lipid deposition in hepatocytes (Fig. 5 H) , suggesting the therapeutic possibility of fatty liver by targeting VEG FR1. Along with improving lipid profile, nonshivering thermogenesis in Flt1 f/f ;Cdh5-Cre-ER T2 mice was significantly higher than it was in control mice (Fig. 5 I) . These findings show that ablation of VEG FR1 in ECs markedly improved metabolic dysfunctions.
In further support, Flt1 f/f ;Tie2-Cre-ER T2 mice also exhibited suppression of HFD-induced gains in body weight and BMI, without affecting food intake in the diet-induced obesity model (Fig. S5, A and B) . Fat mass was also significantly decreased in Flt1 f/f ;Tie2-Cre-ER T2 mice relative to that of control mice (Fig. S5 C) . Glucose and insulin tolerance tests showed obvious improvements in glucose clearance and insulin sensitivity in the HFD-fed, obese mice (Fig. S5, D and E) . Again, HFD-induced hepatic steatosis was significantly suppressed relative to that of control mice (Fig. S5 F) . Taken together, in two genetic models, we show that deletion of VEG FR1 in ECs produced significant improvements in body weight reduction without affecting food intake, blood lipid profile, insulin sensi- deletion of VEG Fr1 in adipocytes and myeloid cells produces no functional effects Because VEG FR1 is expressed in many cell types, including adipocytes and myeloid cells (Kerber et al., 2008; Cao, 2009; Beck et al., 2010; Liu et al., 2012) , blocking VEG FR1 might have autonomous effects on these cells, which eventually affects the global metabolism. Although UCP1 expression in differentiated mature adipocytes was unchanged by anti-VEG FR1 (Fig. 6 A) , we generated two genetic mouse strains, Flt1 ;LysM-Cre, in order to rule out these possibilities. VEG FR1 deletion from either adipocytes or myeloid cells was acheived by crossing Flt1 f/f mice with Adipoq-Cre and LysM-Cre mice, respectively. However, adipose angiogenesis, adipocyte morphology, and UCP1 expression levels remained unchanged in Flt1 f/f ;Adipoq-Cre mice relative to WT control mice (Fig. 6, B and C) .
To exclude the involvement of inflammatory cells that often express VEG FR1 in our experimental settings, we generated a Flt1 f/f ;LysM-Cre genetic mouse strain carrying a specific deletion of VEG FR1 in monocytes/macrophages and CD11b + splenic dendritic cells, neutrophils, and some B cells (Sander et al., 2008; Gordts et al., 2014; Howangyin et al., 2016) . Despite sufficient deletion of VEG FR1 in CD11b ;LysM-Cre mice, no alteration in adipose angiogenesis, adipocyte morphological phenotypes, and UCP1 expression were observed compared with those of WT littermate control mice (Fig. 6, D-F) . In addition, adipocyte and myeloid deletion of VEG FR1 did not significantly alter macrophage populations relative to their respective controls (Fig. S5, G and H) . Furthermore, cytokines inducing browning-IL-4, -6, and -10-were unchanged in pharmacological inhibition and genetic deletion of endothelial VEG FR1 experimental models (Fig. S5, I -K). These data exclude the potential autonomous effect of VEG FR1 on non-ECs. dIscussIon Increasing evidence shows that blood vessels in adipose tissues play an important role in controlling adipose tissue functions . WAT browning and activation of BAT concomitantly switch to an angiogenic phenotype as adipocytes undergo thermogenic reprogramming (Xue et al., 2009; Seki et al., 2016) . Several key questions around these two concomitant processes need mechanistic efforts to gain insights. These include the following: (a) which of these two processes occurs first during browning; (b) which process plays a predominant role in controlling thermogenesis; and (c) would intervention of one process affect the other? It was originally thought that hypervascularization in the metabolically active beige WAT and BAT provided fuel for energy consumption and metabolic changes in adipocytes would be the initial trigger for angiogenesis (Asano et al., 1997) . However, our previous findings have changed this view because genetic deletion of UCP1 does not affect cold-induced angiogenesis in browning WAT and BAT (Xue et al., 2009; Dong et al., 2013) . Thus, adipocyte-derived metabolites cannot be the primary driving force for switching to the angiogenic phenotype.
The angiogenic program in browning WAT and BAT is tightly controlled by a metabolic-independent mechanism. Our recent studies show that VEGF is the key factor responsible for the angiogenic switch in browning WAT under cold exposure (Xue et al., 2009; Dong et al., 2013) . Blocking of VEGF or VEG FR2 signaling completely inhibits adipose angiogenesis (Xue et al., 2009; Honek et al., 2014) , demonstrating the crucial role of VEGF-VEG FR2 signaling in cold-induced angiogenesis. Moreover, genetic deletion of VEG FR2 in ECs also partly prevents angiogenesis in browning adipose tissues . Interestingly, blocking the VEGF-VEG FR2 signaling pathway significantly affects CL-induced WAT adipocyte browning. Because VEG FR2 is exclusively expressed in blood vessel ECs, but not in adipocytes, these genetic and pharmacological loss-of-function data demonstrate the existence of a paracrine loop in which ECs control adipocyte functions.
Our time-course experimental data showed that angiogenesis was initiated several days before the browning of WAT. This intriguing finding supports the fact that angiogenesis occurs independent of adipocyte metabolic status. These data also provide compelling evidence to support our view of the primary function of adipose vasculature in regulating adipocyte functions. Thus, vascular changes occur before adipocyte changes.
Physiological functions of VEGF and its receptor VEG FR1 remain largely uncharacterized (Cao, 2009) ;Cdh5-Cre-ER T2 mice (n = 5 mice/group) and O 2 consumption data presented as AUC (n = 5 mice/group). *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s. = not significant by the standard Student's t test for pair comparisons and ANO VA analysis for multiple factors. Bars, 50 µm. Data are presented as means ± SEM. Experiments were independently repeated twice. tion of VEGF functions (Cao, 2009) . We show the suppressive role of VEG FR1 in WAT vascular homeostasis under physiological functions. Surprisingly, inhibition of VEG FR1 alone, without any exogenous stimulation with growth factors, augmented a robust angiogenic response. Interestingly, anti-VEG FR1 also significantly increased VEGF expression, which could be the driving force for inducing browning. Why would anti-VEG FR1 treatment increase VEGF expression? At the time of writing, the exact mechanism underlying the anti-VEG FR1-triggered VEGF expression is unknown. However, we speculate that browning adipocytes might produce higher levels of VEGF than the quiescent white adipocytes, as seen in other experimental settings . Once the browning phenotype is initiated in the adipose tissue, VEGF production might be elevated.
Our findings are in sharp contrast to a recent study showing the positive role of VEGF-B-VEG FR1 signaling in the modulation of adipose metabolism (Robciuc et al., 2016) . Our data differ from their findings: (a) our experimental settings were under physiological conditions without introducing any exogenous factors, whereas the study by Robciuc et al. (2016) used a VEGF-B-expressing, adeno-associated vector; (b) because VEG FR1 binds to both VEGF-B and PlGF, it is highly plausible that PlGF also plays an important physiological role in adipose metabolism. Pharmacological and genetic ablation of VEG FR1 would block the physiological functions of both factors. Thus, our approaches address broader physiological functions that were not limited to VEGF-B; (c) the previous study cannot exclude the autonomous role of VEGF-B-VEG FR1 on adipocytes and other nonvascular cells, whereas our genetic ;LysM-Cre mice (n = 5 mice/group). (F) Data were quantified from 10 random fields. ***, P < 0.001; n.s. = not significant by the standard Student's t test for pair comparisons. Bars, 50 µm. Data are presented as means ± SEM. Experiments were independently repeated twice. models, with specific ablation of EC VEG FR1, produced an overt browning phenotype; and (d) VEG FR1 is also known to be expressed in non-ECs, including adipocytes and myeloid cells (Cao, 2009; Liu et al., 2012) . Thus, it is plausible the VEG FR1 + non-ECs might play a crucial role in regulating adipose function. The authors of the previous study investigated only the role of endothelial VEG FR1 in regulating adipocyte function. We used two additional genetic mouse models to address this important issue. Specific genetic deletion of VEG FR1 in adipocyte and myeloid did not produce overt phenotypes, hence, excluding the non-EC VEG FR1 function in adipose metabolism.
Browning of WAT by genetic deletion of endothelial VEG FR1 establishes a paracrine regulatory loop in which ECs control adipocyte metabolism (Fig. 7) . Pharmacological and genetic ablation of VEG FR1 may switch VEGF to VEG FR2 signaling and thereby enhance the VEG FR2-mediated angiogenesis. Indeed, dual blocking VEG FR1 and VEGF by a combination of VEGF and VEG FR1 blockades completely prevents an angiogenic phenotype in WAT. Similarly, dual inhibition of VEG FR1 and VEG FR2 completely blocked anti-VEG FR1-induced angiogenesis and WAT browning. These data suggest that VEGF, but not other VEG FR1 ligands, is the primary driving force in VEG FR1 inhibition-triggered angiogenesis. VEGF-dependent angiogenesis in the absence of VEG FR1 indicates that VEG FR2 transduces active signals. The functional switch from negative VEG FR1 to positive VEG FR2 without excessive VEGF suggests the existence of an extremely sensitive balance between these two receptors. At the molecular level, we also show that anti-VEG FR1 treatment alone is able to induce VEG FR2 phosphorylation in WAT. Under physiological nonbrowning conditions, VEG FR1 predominates its functions by preventing vessel growth. In fact, VEGF binds to VEG FR1 with 10-fold higher affinity than it does to VEG FR2 (Hiratsuka et al., 2001 ). When VEGF is expressed at a modest level, it preferentially binds to VEG FR1, not VEG FR2. All these data support the general view that VEG FR1 serves as a negative regulator of adipose angiogenesis. Thus, adipose vasculatures remain quiescent under physiological conditions. Blocking VEG FR1 redirects VEGF to interact with VEG FR2, which induces angiogenesis. This is a tightly regulated system, and the expression level of each ligand and receptor should be optimal, otherwise creating situations of too few or too many microvessels in the fat tissues. Optimal expression of VEGF is crucial during embryonic development, as demonstrated by haploinsufficiency being lethal in mice carrying only one functional VEGF allele i.e., lowering the amount of VEGF to half (Carmeliet et al., 1996; Ferrara et al., 1996) . Along with this observation, our recent studies demonstrated the existence of a paracrine regulatory mechanism in which angiogenic ECs produce platelet-derived growth factor (PDGF)-CC to control preadipocyte differentiation into beige adipocytes ). It appears that the VEGF-EC-PDGF-preadipocyte axis operates WAT browning. Thus, blocking either VEGF-VEG FR2 signaling or PDGF-CC-PDG FRα signaling could effectively inhibit browning.
Ablation of VEG FR1 in ECs also markedly inhibits obesity in HFD-fed mice by reducing WAT masses. Strikingly, mice lacking VEG FR1 do not seem to develop liver Because VEGF preferentially binds to VEG FR1 with a 10-fold higher affinity than VEG FR2, a limited number of VEGF ligands would preferentially bind to VEG FR1, which acts as a decoy receptor. However, blocking VEG FR1 would reinforce VEGF binding to VEG FR2, which transduces angiogenic signals. It is known that angiogenic ECs produce paracrine factors to convey a browning phenotype of WAT. Browning adipocytes consume excessive energy through activation of a nonshivering thermogenesis mechanism.
steatosis and show improvement in insulin sensitivity and in their blood lipid profiles. Based on these findings, we propose that pharmacological blocking of VEG FR1 provides a novel therapeutic approach for treatment of obesity, liver steatosis, and diabetes. Given clinically available anti-VEGF and anti-VEG FR2 drugs for treatment of cancer and eye disease, development of an anti-VEG FR1-neutralizing antibody for treatment of metabolic disease would be a straightforward and feasible therapeutic approach. Another interesting notion is that ablation of VEG FR1 could further augment other agent-induced browning phenotypes of WAT. In this study, we showed that deletion of VEG FR1 further augmented β3 adrenoceptor CL-316,243-induced angiogenesis and browning. These findings would suggest that a combination of anti-VEG FR1 agents with the known WAT browning agents would produce greater effects on nonshivering thermogenesis and ultimately provide metabolic improvement in the treatment of type 2 diabetes and other metabolic diseases.
MAtErIAls And MEtHods Animals
C57Bl/6 mice were obtained from the breeding unit at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institute (Stockholm, Sweden). For all experiments, mice were randomly divided into groups. All mouse studies were approved by the Northern Stockholm Experimental Animal Ethical Committee.
Antibodies and reagents
Dexamethasone (DEX), insulin, 3-isobutyl-1-methylxanthine (IBMX), isoproterenol, and tamoxifen were purchased from the Sigma-Aldrich. Primer sequences for all PCR and quantitative PCR (qPCR) experiments are listed in Table S1 . Hepes, DMEM, and lysine-fixable fluorescein dextran at a molecular mass of 70 kDa (D1822) or 2,000 kDa (D7137) were purchased from the Thermo Fisher Scientific Inc. Antibodies included a rat anti-mouse endomucin antibody (14-5858-85; eBioscience), a rabbit anti-mouse UCP1 antibody (10983; Abcam), a rat anti-mouse CD31 antibody (553370; BD Pharmingen), a rat anti-mouse VEG FR1 antibody (MF1; ImClone Systems), and an anti-mouse β-actin antibody (3700S; Cell Signaling Technology).
cell culture and treatment 3T3F442A preadipocytes were cultured and maintained in DMEM supplemented with 10% FBS, 100 units/ml penicillin, and 100 µg/ml streptomycin. Cell differentiation was induced for 48 h with a DMEM medium containing 850 nM insulin, 0.5 mM IBMX and 0.1 µM DEX, followed by treatment with 850 nM insulin for subsequent 7-10 d. After 10-d induction of differentiation, cells were treated with a rat anti-mouse VEG FR1 (anti-R1) neutralizing antibody or a nonimmune IgG (NIIgG) for 24 and 72 h. UCP1 expression was determined by qPCR.
Pharmacological blocking of VEG Frs
For pharmacological treatment, female, WT C57Bl/6 mice at 7-to 8-wk-old received treatment of a specific anti-mouse VEG FR1 (20 mg/kg, i.p., twice per week, 3-4 times during the entire experiment), an anti-VEG FR2 (20 mg/kg, i.p., twice per week, 3-4 times during the entire experiment), or NIIgG for 10 d (n = 8 mice per group per experiment). These treatment regimens have been known to effectively block their targeted signaling pathways. Treated mice were subjected for metabolic analysis, followed by sacrifice and tissue collection. NIIgG-treated mice using the same regimens served as control groups.
Vascular permeability and perfusion
Vascular perfusion and permeability assays were performed according to our previously published methods (Rouhi et al., 2010; Lim et al., 2012 Lim et al., , 2014 Hosaka et al., 2013; Seki et al., 2016; Zhang et al., 2016) . Briefly, lysine-fixable fluorescein dextrans with molecular masses of 70 kDa or 2,000 kDa were injected into the tail vein of each mouse receiving anti-VEG FR1 or NIIgG treatment as described in the main text. At 5 and 15 min after injections with 2,000 kDa and 70 kDa, respectively, mice were sacrificed, and various adipose depots were immediately fixed with 4% paraformaldehyde overnight for whole-mount staining. The leakage and perfusion were quantified by microscopic-captured images using an Adobe Photoshop CS software program.
Genetic deletion of VEG Fr1 in various mouse trains
The global VEG FR1 KO mice were generated by crossing Flt1 f/f mice with Rosa26-Cre-ER T2 in a C57Bl/6-and S129-mixture background. Mice were maintained by backcrossing in the C57Bl/6 background (provided by G.-H. Fong, University of Connecticut Health Center, Farmington, CT; Fong et al., 1995) . The myeloid cell linage-specific, VEG FR1-deficient mice were generated by crossing the Flt1 f/f mice with LysM-Cre in a C57Bl/6 background (provided by M. Rottenberg, Karolinska Institute, Stockholm, Sweden). The adipocyte-specific, VEG FR1-deficient mice were generated by crossing the Flt1 f/f mice with Adipoq-Cre mice in a C57Bl/6 background (provided by C. Ibanez, Karolinska Institute). The EC-specific, VEG FR1-deficient mice were generated by crossing Flt1 f/f mice with Tie2-Cre-ER T2 or Cdh5-Cre-ER T2 mice in C57Bl/6 backgrounds (generated by A. Bernd and provided by the European Mouse Mutant Archive and R. Adams, Max Planck Institute for Molecular Biomedicine, Muenster, Germany, respectively.). These transgenic strains were identified by genotyping using either ear or tail DNA and a PCR-based method. The specific primer sequences for genotyping are showed in Table S1 . The global and EC deletion of the Vegfr1 gene was achieved by treating mice with tamoxifen.
For generation of the global Vegfr1 KO strain, the Flt1 ;Tie2-Cre-ER T2 mice was achieved by tamoxifen induction (2 mg/ mouse, i.p., once daily for a consecutive 5 d). About 8-10 d after the last tamoxifen injection, mice were analyzed for metabolism, followed by euthanasia and tissue collection. For the diet-induced obese model, the mice were maintained under standard animal housing conditions and were fed with either standard diet or HFD (D12492; Research Diets Inc.).
Isolation of mature adipocyte fraction (MAF) and stromal vascular fraction (sVF)
The primary MAF and the SVF from subWAT of WT and tamoxifen-treated conditional KO mice were fractioned with a collagenase-digestion-based method . Tissues were collected, minced, and digested at 37°C for 0.5 h in a collagenase-digestion solution (0.15% collagenase II, 10 mM Hepes, and 5% BSA in DMEM). During digestion, the suspension was triturated with a vortex every 5 min and eventually quenched on ice for 5 min, followed by centrifugation at 300 g for 5 min. The floating adipocytes were collected, washed with PBS, and centrifuged at 300 g for 10 min. The floating adipocytes were harvested as MAF. The remaining suspension was passed through a 70-µm mesh to remove undigested debris, and effluents were centrifuged at 300 g for 10 min. The SVF pellet was washed once with PBS. Cells in SVF were subjected to magnetic-activated cell sorting (MACS) for isolation of either CD31 + or CD11b + cell populations for assessing KO efficiency. SVF cells were incubated using an anti-mouse CD31 microbeads antibody (130-097-418; Miltenyi Biotec) or a PE-labeled rat anti-mouse CD11b antibody (101208; BioLegend), followed by staining with a magnet-conjugated anti-PE antibody (120-000-294; MACS). Stained cells were separated with MACS columns and an OctoMACS separator MACS) according to the manufacturer's instruction (MACS). Gene expression levels were quantitatively measured by qPCR.
Metabolic measurements NE-induced thermogenesis and whole-body energy metabolism were quantified by measuring the oxygen consumption of each mouse over defined time points using the Oxymax CLA MS-HC System (Columbus Instruments). The Oxymax machine was kept at 30°C, and the oxygen sensor was heated up for at least 6 h before calibration with the reference gases: 100% nitrogen gas and a mixture of 20.5% O 2 and 0.5% CO 2 . For the whole-body energy metabolism, CO 2 and O 2 were measured, and the data were collected every 25 min for each mouse. Metabolic rates were measured as baselines for 24 h before s.c. NE injection (1 mg/kg). The area under the curve (AUC) of the volume of oxygen (VO 2 ) consumed was calculated for a period of 60 min before NE injection until 160 min after injection. NE-induced thermogenesis for the VEG FRs blockade (Fig. 1 I) was determined by an assessment of oxygen consumption using an open-circuit indirect calorimeter INCA system (Somedic INCA). During the measurement, the mice were anaesthetized, and the basal metabolic rate was measured before NE injection.
Glucose and insulin tolerance tests
Mice were fasted for 6 h during the light phase, with free access to water on the day of the tests. Blood samples collected from the tail vein were used to measure glucose levels with a glucometer (Accu-Chek Aviva; Roche Diagnostics) immediately before and at 15, 30, 60, and 120 min after oral feeding with 1.5 mg glucose and 10 µl/g body weight and i.p. injection of insulin (0.5 U/kg-body weight), respectively.
Blood lipid profiling FFA, glycerol, cholesterol, and TG were measured with a sensitive assay kit (ab65341, ab65337, ab65359, ab65336; Abcam). Blood insulin was measured with a sensitive ELI SA kit according to the manufacturer's instruction (10-1247-01; Mercodia). Blood was collected by cardiac puncture. Mice were fasted for 6 h before sacrifice and blood collection.
Histology and immunohistochemistry
Paraffin-embedded tissue sections in 5-µm thickness were stained with hematoxylin and eosin (H&E) using our standard protocol Iwamoto et al., 2015; Seki et al., 2016) . For UCP1 and CD31 staining, the paraffin-embedded tissue sections were incubated with a rabbit anti-mouse UCP1 antibody (1:200; Abcam) and a rat anti-mouse CD31 antibody (1:200), followed by staining with a mixture of secondary antibodies comprising an Alexa Fluor 555-labeled goat anti-rat antibody (1:200; Invitrogen) and an Alexa Fluor 649-labeled goat anti-rabbit antibody (1:400; Jackson ImmunoResearch Laboratories Inc.). Positive signals were captured with a fluorescence microscope equipped with a Nikon DS-QilMC camera. A rat anti-mouse VEG FR1 antibody (1:100 dilution in blocking buffer) was used for incubation at 4°C overnight. A secondary goat anti-rat Alexa 555 antibody (A21434; 1:200 dilution; Invitrogen) in blocking buffer was incubated at room temperature for 1 h. For lipid staining, Oil Red O staining was performed according to the BioVision manual. In brief, frozen liver sample was fixed with 4% paraformaldehyde for 30 min, washed with 60% isopropanol, and stained at 37°C with Oil Red O (O1391; Sigma-Aldrich) solution for 15 min. Nuclei were counterstained with hematoxylin for 10 min, mounted with glycerol, and examined under a light microscope.
Whole-mount staining Whole-mount staining was performed according to our previously published, standard method Iwamoto et al., 2015; Seki et al., 2016) . Paraformaldehyde-fixed subWAT, visWAT, and interscapular BAT (iBAT) tissue samples were digested with proteinase K (20 µg/ml) for 5 min and blocked with skim milk, followed by staining overnight at 4°C with a rat anti-mouse CD31 antibody (1:200). After rigorous rinsing in PBS, blood vessels were detected with an Alexa Fluor 555-labeled secondary antibody, mounted in Vectashield mounting medium (Vector Laboratories, Inc.), and stored at -20°C in darkness before examination under a Nikon C1 confocal microscope. Captured images were further analyzed using an Adobe Photoshop CS software program.
rnA isolation, rt-Pcr, and qPcr analyses Total RNA was extracted from cells and tissues using TRIzol (Invitrogen) and GeneJET RNA purification kits according to the manufacturer's instructions. The total RNA was reversely transcribed, and cDNAs were used for PCR and qPCR analyses using the primers listed in Table S1 . Samples were stored at −20°C and subjected to qPCR using an ABI Prism 7500 System (Applied Biosystems). Each qPCR sample was performed in triplicate, and the 20-µl reaction contained Fast SYBR Green (4385612; Applied Biosystems), 150 nM forward and reverse primers, and 1 µl cDNA. The qPCR protocol was executed for 40 cycles, and each cycle consisted of denaturation at 95°C for 15 s, annealing at 60°C for 1 min, and extension at 72°C for 1 min.
Western immunoblotting subWAT tissues were lysed with protein extraction regent (C3228; Sigma-Aldrich) in the presence of a proteinase inhibitor (8340; Sigma-Aldrich) and a phosphatase inhibitor cocktail (5870; Cell Signaling). For VEG FR2 phosphorylation analysis, an equal amount of total protein extract from each tissue lysate was incubated overnight with Protein G-Agarose immunoprecipitation using an anti-phospho-tyrosine antibody (APY03; Cytoskeleton). For CD31 detection, equal amounts of total protein were applied. Tissue samples along with a size marker were loaded on an SDS-PAGE gel (NP0321/NP0323; Life Technologies), followed by transferring onto a nitrocellulose membrane (88018; Thermo Fischer Scientific). After blocking with 3% skim milk, membranes were incubated with a rabbit anti-VEG FR2 (2479; Cell Signaling) antibody, a goat anti-CD31 (AF3628; R&D system) or a mouse anti-β-actin (3700; Cell Signaling) antibody, followed by incubating with an anti-rabbit IRDye-680RD-labeled secondary antibody (926-68073; LI-COR), an anti-goat IRDye 800CW-labeled secondary antibody (926-32214; LI-COR), an anti-mouse IRDye 680RD labeled secondary antibody (926-68072; LI-COR), or an anti-mouse IRDye-800CW-labeled antibody (926-32212; LI-COR). Positive signals were visualized and quantified using Odyssey CLx system (LI-COR).
statistical analysis
Statistical analysis was performed using the standard Student's t test for pair comparisons and ANO VA for multiple factors. Data are presented as means ± SEM of determinants, and values of P < 0.05 were deemed statistically significant. online supplemental material Fig. S1 shows that blocking VEG FR1 augments adipose angiogenesis, visWAT browning, and iBAT activation. Fig. S2 shows that genetic elimination of VEG FR1 induces angiogenesis, visWAT browning, and iBAT activation. Fig. S3 shows that endothelial deletion of VEG FR1 augments angiogenesis and visWAT browning in Flt1 f/f ;Tie2-Cre-ER T2 mice. Fig. S4 shows that deletion of endothelial VEG FR1 in Flt1 f/f ;Cdh5-Cre-ER T2 mice induces visWAT angiogenesis and browning. Fig. S5 shows that conditional KO of VEG FR1 in ECs of Flt1 f/f ; Tie2-Cre-ER T2 mice increases antiobesity activity. Table S1 shows the sequences of the primers used in the experiments.
